Protalix BioTherapeutics (FRA:PBDA) Other Net Income (Loss) : €0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2008. Start your Free Trial

What is Protalix BioTherapeutics Other Net Income (Loss)?

Protalix BioTherapeutics's Other Net Income (Loss) for the three months ended in Dec. 2024 was €0.00 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2024 was €0.00 Mil.

Protalix BioTherapeutics's annual Other Net Income (Loss) declined from Dec. 2022 (€0.00 Mil) to Dec. 2023 (€-0.00 Mil) but then increased from Dec. 2023 (€-0.00 Mil) to Dec. 2024 (€0.00 Mil).

Protalix BioTherapeutics Other Net Income (Loss) Historical Data

The historical data trend for Protalix BioTherapeutics's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Protalix BioTherapeutics Other Net Income (Loss) Chart

Protalix BioTherapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Net Income (Loss)

Get a 7-Day Free Trial

Protalix BioTherapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Other Net Income (Loss)	Get a 7-Day Free Trial															-	-	-	-	-

Protalix BioTherapeutics Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Protalix BioTherapeutics Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Protalix BioTherapeutics's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Protalix BioTherapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protalix BioTherapeutics Inc (FRA:PBDA) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

PLX:USA

Address

2 University Plaza, Suite 100, Hackensack, NJ, USA, 07601

Website

https://www.protalix.com

Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.

Protalix BioTherapeutics Headlines

No Headlines